Codexis Reports Third Quarter 2024 Financial Results
Codexis, Inc. (CDXS)
Last codexis, inc. earnings: 2/27 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.codexis.com/investors
Company Research
Source: GlobeNewswire
Quarter Highlights Include Key Additions to Management Team and Extension of Cash Runway into 2027 with $31M Raise via ATM Facility Company Reiterates Full-year Financial Guidance; On Track to Achieve Product Revenue Growth of at Least 10% vs. FY2023 Excluding Enzyme Sales Related to PAXLOVID™ REDWOOD CITY, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced financial results for the third quarter ended September 30, 2024, and provided a business update. “Codexis had a strong third quarter, in which we surpassed product revenue goals, welcomed two new, highly experienced executives to our management team, and brought in $31 million via our existing ATM facility, extending our cash runway into 2027, past the point of profitability. By out-licensing our genomics enzymes portfolio to Alphazyme, we also reinforced our ability to focus on our key strateg
Show less
Read more
Impact Snapshot
Event Time:
CDXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CDXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CDXS alerts
High impacting Codexis, Inc. news events
Weekly update
A roundup of the hottest topics
CDXS
News
- Codexis to Participate in Piper Sandler 36th Annual Healthcare ConferenceGlobeNewswire
- Biofuel Enzyme Global Market Overview 2024: Blending Mandates and Bioethanol Adoption Fueling the $2.5 Billion Market - Forecasts to 2030 [Yahoo! Finance]Yahoo! Finance
- Codexis, Inc. (NASDAQ: CDXS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $11.00 price target on the stock.MarketBeat
- Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics [Yahoo! Finance]Yahoo! Finance
- Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi TherapeuticsGlobeNewswire
CDXS
Earnings
- 10/31/24 - Miss
CDXS
Sec Filings
- 11/14/24 - Form SCHEDULE
- 11/12/24 - Form 4
- 11/12/24 - Form 3
- CDXS's page on the SEC website